The litigation alleges that GeneDx misled shareholders regarding the integration and financial impact of its acquisition of Fabric. While the company publicly championed the deal, claiming it would optimize dry lab processes and reduce costs, the lawsuit contends these statements were false. Plaintiffs assert that executives either knew of or recklessly disregarded significant viability issues within Fabric that ultimately harmed the company’s financial health and damaged investor interests once the truth reached the market.

Investors are not required to take action to remain part of the potential class, though those wishing to serve as lead plaintiff must file a motion with the court by the August deadline. Participation as a lead plaintiff is not a prerequisite for sharing in a future settlement. Individuals interested in the case can contact attorney Phillip Kim at the Rosen Law Firm for further guidance on the legal proceedings.